

Markets update

Nadège Dufossé

Head of Cross-Asset Strategy & Deputy Global Head of Multi-Asset


1 October 2020

Widening performance gaps post lockdown easing

The persistence of COVID-19 pandemic has benefited growth stocks and "safe assets"



Eurozone large caps have performed within a 10% range since June (3100-3400)







Investors' sentiment has improved

Sentiment indicators show a mixed picture

Sentiment indicators are neither too optimistic nor too pessimistic



A majority of strategists in surveys now believe that the bull market is not over



Source: BofA Global Fund Manager Survey

Sources: Bloomberg, BofA Merrill Lynch, Candriam Cross-Asset Strategy



Can some gaps be filled?


Conditions for a rotation

Driver	Assessment	+	-
Economic momentum	The pace of positive surprises is likely to slow down towards the end of 2020, following a V-shaped recovery in Q3. High-frequency data will also continue to drive markets over the short term.		
Covid-19: Vaccine Vs. Second Wave	A new wave of infections in economically vital countries leading to lockdowns would make a strong negative impact. A vaccine made available would be a strong positive factor.		•
US elections uncertainty	Volatility around the uncertain outcome of the US elections is a negative factor. Expansionary Macro alignment: higher spending (Biden) vs. lower taxes (Trump) in an accommodative Fed context.		
Direction of interest rates	Real rates have reached a trough (positive), modest steepening could continue. New FOMC policy framework is more negative (lower rates for longer).		
Strong momentum and relative valuation	Growing valuation (and performance) gap between Momentum / Growth and Value.		

After a strong rebound in Q3, economic indicators should stabilise in Q4

Economic surprises indices have rolled over, high frequency data to drive short-term performance

High frequency indicators can be used to assess the



October 2020 Commercial document intended exclusively for Professional Investors

5

A NEW YORK LIFE INVESTMENTS COMPANY

Waiting for a vaccine or an efficient treatment


Markets remain caught between the threat of the second wave and hope for a vaccine

Our World in Data

While the US situation is improving, Europe is now facing a rapid rise in COVID-19 cases

Daily new confirmed cases of COVID-19 per million people The line is blue when the rate of positive tests in a country is low – this means a country performs many tests relative to the size of the outbreak.

Red indicates a high positive rate of tests. This suggests that the true number of infections may be far higher than the number of confirmed cases.




Source: European CDC - Situation Update Worldwide - Last updated 28 September, 10:05 (London time), Official data collated by Our World in Data

Note: Only countries for which testing data is available are included. Details about this data can be found at OurWorldInData.org/coronavirus-testing.

OurWorldInData.org/coronavirus • CC BY

Three COVID-19 vaccines could be approved by the end of 2020

Figure 1. COVID vaccine timelines across candidates




Sources: Barclays, Candriam Cross-Asset Strategy



US Elections, another game changer?

Uncertainty around the US election results is largely priced in



Sources: Bloomberg, Candriam Cross-Asset Strategy

Who will be President? What kind of Congress? Unity or devision?

The impact on the global economy and markets is an equation with several unknowns

	Election of Joe Biden	Re-election of Donald Trump
	His programme may produce significant reversals on the domestic market.	On the basis that his election programme is the same as in 2016
Election programme	Joe Biden's election will be more destabilising for the US domestic market than for the rest of the world. There will be considerable economic support, but it will be applied differently: tax rises, minimum wage increases, infrastructure investment plans, taking the climate and more sustainable development into account. The healthcare sector is also a major divergence point, and the move towards deregulation is likely to stop.	Domestic policy will be marked by a certain continuity, with the key points of tax cuts, continued deregulation and restrictions on immigration. His policies would avert regulatory risks for companies in the oil and health sectors.
	US international relations will be able to regain a more traditional and less chaotic footing, with the return of multilateralism. In this scenario, the strategic, economic and trade dialogue with Europe would be re-established.	Foreign policy remains the main cause of uncertainty, although we still anticipate less multilateralism and a strong line with China.
What impacts can we anticipate	The sectoral impact on the US domestic market will probably be greater. It will be positive in the infrastructure and transport sectors, renewable energies and more generally on issues relating to sustainable development. Conversely, the impact will be more negative on healthcare and energy (oil and gas).	Foreign policy was destabilising for non-US assets during the President's first mandate. Risky assets in China, emerging countries and Europe could suffer as a result of US protectionist pressures, as has been the case over the past four years. Political risk will continue to be a key factor for the financial markets.
on the markets?	Non-US assets could benefit from more constructive and less chaotic relations. Europe and emerging countries are unlikely to see their performance negatively impacted by unpredictable political risk.	On the US domestic market, the re-election of Donald Trump could favour a reduction in the risk premium on the energy and healthcare sectors.

Sources: Candriam Cross-Asset Strategy



A blue wave would first make an impact with the domestic market

Equity sector impact of a blue wave Vs. continuity of current policy

	Trump mandate	Obama la mandate	ast	Alternative Energy (2trn USD investment in
Performance TR USD		-06 Nov 12 - 07 Nov 16		renewables) Vs. Old Energy
MSCI USA	56.6%	62.1%		
Energy	-54.7%	2.7%		
Materials	30.6%	40.4%		
Industrials	31.5%	67.1%		
Capital Goods	16.6%	66.3%		
Commercial & Professional Services	77.6%	75.5%		
Consumer Discretionary	105.1%	77.6%		
Automobiles & Components	146.4%	48.2%		
Consumer Durables & Apparel (Luxury Goods)	46.4%	41.2%		
Consumer Services	43.0%	60.0%		
Retailing	149.8%	105.4%		
Consumer Staples	18.8%	64.7%		
Food & Staples Retailing	48.9%	55.5%		Biden to expand Medicaid and ACA, lower
Food, Beverage & Tobacco	-2.7%	77.7%		Medicare eligibility age – impact will depend
Household & Personal Products	49.6%	44.2%	7	
Healthcare	54.3%	82.7%		on the composition of Congress. Major
Equipment	79.1%	91.5%		Pharma have 50% exposure outside the US.
Pharmaceuticals	38.9%	78.2%		
Financials	16.4%	63.3%		A potential Democratic victory has raised
Banks	-0.3%	56.4%		concerns about taxes and regulations, and
Diversified Financials	37.9%	64.0%	<pre>></pre>	
Insurance	9.7%	75.7%		would have the strongest impact on that
Technology	152.8%	81.7%		sector (banks, brokers, asset managers).
Software & Services	144.3%	91.0%	·	
Hardware	186.2%	55.5%		
Semiconductors	127.6%	123.2%		
Communication Services	32.7%	30.0%	Z	Support anti-trust legislation
Media	68.4%	76.8%		
Utilities	17.8%	56.9%		

Sources: Bloomberg, Candriam Cross-Asset Strategy



Is there any impact outside the US?


Non-US assets could benefit from more constructive and less chaotic politics

erformance TR	08 Nov 16 - 25 Sep 20	06 Nov 12 - 07 Nov 16		
S&P 500	54%	63%		
Eurostoxx 50	4%	38%	┃>	Europe suffered the most during Tru
FTSE 100	-15%	34%	/	mandate
MSCI Emerging markets	17%	-1%	-	
MSCI China	53%	16%	and the second	
Nikkei	35%	105%	and the second	
DAX 30	19%	42%		
CAC 40	6%	47%	1 th	
FTSEMIB	11%	21%		
BEX	-26%	36%		
SMI	32%	30%		



Direction of interest rates, key for a possible rotation

Acceleration of "momentum" trades supported by the historical decrease of US real rates



This powerful trend in US real rates has benefited gold... 2200 -,1.50 2000 -,1.00 1800 -,0.50 1600 .0.00 1400 ,0.50 1200 ,1.00 1000 800 ,1.50 Jan-14 Jan-15 Jan-16 Jan-17 Jan-18 Jan-19 Jan-20 -----Gold ...and also growth stocks' valuations -,1.50 12 -,1.00 8 -,0.50 4 ,0.00 .0.50 0 ,1.00 -4 ,1.50 -8 ,2.00 Jan-14 Jan-15 Jan-17 Jan-18 Jan-19 Jan-20 Jan-16

S&P500, 12 months forward PE yoy change


— US Real Yields (RHS)



A possible comeback of unloved stocks?

There is a risk of reversal in the life "after COVID-19"...

Evolution of "growth" style performance relative to "value" YTD 2020: a gap of between 30% and 40%...




...the contrast is even stronger between companies that have benefited from the pandemic ("stay at home") and companies that are severely hit ("back to work")



Sources: Bloomberg, Exane BNP Paribas, Candriam Cross-Asset Strategy

Equity valuations not excessive if we discount a cyclical rebound


Valuations remain correlated to profit growth






Credit and equity valuations are now close to their historical median

The upside of Eurozone equity valuations dependant on the decrease of the (political) risk premium



Credit spreads are close to their median historical

Equity relative valuation to bonds now closer to its median since 2008




Sources: Bloomberg, Candriam Cross-Asset Strategy

A NEW YORK LIFE INVESTMENTS COMPANY

Cross-Asset views

Q4 key messages



October 2020



Important Disclosure

This document is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performances of a given financial instrument or index or an investment service, or simulations of past performances, or forecasts of future performances are not reliable indicators of future performances. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change.

The present document does not constitute investment research as defined by Article 36, paragraph 1 of the Commission delegated regulation (EU) 2017/565. Candriam stresses that this information has not been prepared in compliance with the legal provisions promoting independent investment research, and that it is not subject to any restriction prohibiting the execution of transactions prior to the dissemination of investment research. Candriam consistently recommends investors to consult via our website www.candriam.com the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value ("NAV") of the funds. This information is available either in English or in local languages for each country where the fund's marketing is approved.

Specific information for investors in Spain: Candriam Luxembourg Sucursal en España has its registered office at C/ Pedro Teixeira, 8, Edif. Iberia Mart I, planta 4, 28020 Madrid and is registered with the Comisión Nacional del Mercado de Valores (CNMV) as an European Economic Area management company with a branch. The following collective investment institutions (IIC) are registered with the CNMV:

mbre de IIC	Num. Reg. CNMV	Domicilio de IIC		Forma Legal	Nombre de IIC	Num. Reg. CNMV	Num. Reg. Domicilio CNMV de IIC	
driam Absolute Return	657	Luxembourg	UCITS	SICAV	Candriam Diversified Futures	1532	1532 France	1532 France UCITS
riam Bonds	266	Luxembourg	UCITS	SICAV	Candriam Global Alpha	1563	1563 France	1563 France UCITS
friam Equities L	233	Luxembourg	UCITS	SICAV	Candriam Index Arbitrage	707	707 France	707 France UCITS
ndriam GF	1392	Luxembourg	UCITS	SICAV	Candriam Long Short Credit	798	798 France	798 France UCITS
ndriam Money Market	644	Luxembourg	UCITS	SICAV	Candriam Monétaire SICAV	1472	1472 France	1472 France UCITS
ndriam Quant	347	Luxembourg	UCITS	SICAV	Candriam Risk Arbitrage	711	711 France	711 France UCITS
ndriam SRI	1493	Luxembourg	UCITS	SICAV	Candriam Sustainable	470	470 Belgium	470 Belgium UCITS
leome Index	1275	Luxembourg	UCITS	SICAV				





www.candriam.com



